Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ribociclib · Kisqali, LEE-011

Small molecule · Inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) · developed by Novartis

Approved FDA, Mar 2017
NVS Developer
1 Registered trials

What is Ribociclib?

Ribociclib is a kinase inhibitor of cyclin-dependent kinases 4 and 6, which are activated by D-cyclins and drive cell cycle progression through phosphorylation of the retinoblastoma protein. By blocking these kinases, it causes G1 phase arrest and reduced proliferation. It is studied in early breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Kisqali, LEE-011, LEE-011A
Drug type
Small molecule
Targets
cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 6 (CDK6)
Mechanism
Inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6)
Pathways
cell cycle progression (G1 to S phase), retinoblastoma protein (pRb) phosphorylation
Therapy area
Oncology
Developer
Novartis (NVS)
FDA status
Approved as Kisqali (March 13, 2017), NDA209092 · FDA label
UNII
TK8ERE8P56

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 1, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05827081 Phase 3 Early Breast Cancer Active not recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Early Breast Cancer

Other drugs acting on CDK4 / CDK6

More from Novartis

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Ribociclib

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.